Uremia Clinical Trial - Elimination of Incretin Hormones in Patients With

Status Completed

Clinical Trial Summary

The prevalence of type 2 diabetes (T2D) is increasing rapidly worldwide. T2D is characterized by a severely impaired incretin effect. The incretin effect refers to the insulinotropic action of the nutrient-released incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). The incretin effect is defined as the difference in insulin secretory responses between oral and isoglycaemic intravenous glucose challenges (OGTT and IIGI, respectively) and in healthy individuals it accounts for as much as 70% of the insulin response following oral glucose, whereas patients with T2D exhibit an incretin effect in the range of 0 to 30%. Patients with T2D and non-diabetic patients with severe kidney failure share several pathophysiological characteristics, including decreased insulin sensitivity, fasting hyperinsulinaemia and impaired beta-cell function. The reason for these findings remains to be fully elucidated. An ongoing study in our research group is investigating the incretin effect and the incretin hormone secretory responses following OGTT, IIGI and meal ingestion, respectively. In continuation of this study, essential knowledge of metabolism of incretin hormones in an uremic milieu will be obtained in the present study prior to evaluation of the use of incretin-based agents in patients with impaired kidney function. In this second study we evaluate the elimination and biodegradation of GLP-1 and GIP. The biological active incretin hormones are rapidly degraded by the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4), generating inactive metabolites. The active hormones are however also eliminated by renal clearance, although the importance of this remains questionable. It is likely that the degradation and elimination of the active hormones will be significantly affected in patients with severe kidney impairment.

We hypothesize that elimination and biodegradation of the two incretin hormones, both in it´s active and inactive forms, will be affected in non-diabetic patients with severe kidney failure.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Uremia

Clinical Trial Details

NCT number	NCT01391884
Study type	Observational
Source	Rigshospitalet, Denmark
Contact
Status	Completed
Phase	N/A
Start date	June 2011
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT00577967` - Gabapentin - A Solution to Uremic Pruritus?	N/A
Completed	`NCT01583309` - Effects of Convective Therapies in Dialysis Patients	Phase 3
Completed	`NCT03437538` - Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter	N/A
Completed	`NCT00649298` - A Clinical Trial of IntensiVE Dialysis	Phase 4
Completed	`NCT05750875` - Gabapentin Versus Loratadine in Uremic Pruritus	Phase 4
Recruiting	`NCT01408797` - Clonal Deletion on Living-Relative Donor Kidney Transplantation	Phase 1/Phase 2
Completed	`NCT01267760` - Clinical and Biochemical Effects of Multipass Hemodialysis	Phase 2
Recruiting	`NCT00375635` - Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis	N/A
Recruiting	`NCT05076318` - Dysregulated Urea-synthesis at Terminal Uremia	N/A
Completed	`NCT05899283` - A Comparative Study of Two Kinds of Hemodialysis Filters	N/A
Completed	`NCT04768309` - Impact of Intestinal Microbiota on Uremic Toxins Productions	N/A
Not yet recruiting	`NCT05386433` - Paxlovid in the Treatment of COVID-19 Patients With Uremia	Early Phase 1
Completed	`NCT00442819` - Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney	Phase 4
Not yet recruiting	`NCT02266238` - Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial	N/A
Recruiting	`NCT01766895` - Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
Completed	`NCT00388648` - Very Low Protein Diet or Dialysis in Uremic Elderly?	Phase 4
Withdrawn	`NCT03416192` - 12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.	N/A
Recruiting	`NCT02446535` - Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?	N/A
Recruiting	`NCT02606955` - Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test	N/A
Completed	`NCT02050139` - L-Cysteine in Peritoneal Dialysis	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Elimination of Incretin Hormones in Patients With Severe Kidney Failure

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms